10/693,161 8/18/05

NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:34:08 ON 18 AUG 2005

=> fil reg
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 12:34:19 ON 18 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 AUG 2005 HIGHEST RN 860672-09-9
DICTIONARY FILE UPDATES: 17 AUG 2005 HIGHEST RN 860672-09-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 18, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=>
Uploading C:\Program Files\Stnexp\Queries\10693161\10693161j.str



chain nodes :
1 2 3 5 6 7 9 10 13 14 21
ring nodes :
15 16 17 18 19
chain bonds :
1-2 1-21 2-3 3-5 5-6 6-7 7-9 9-10 10-13 10-14
ring bonds :
15-16 15-19 16-17 17-18 18-19
exact/norm bonds :
1-2 1-21 2-3 3-5 5-6 6-7 7-9 9-10 10-13 10-14 15-16 15-19 16-17 17-18
18-19

G1:O,S

Match level :
1:CLASS 2:CLASS 3:CLASS 5:CLASS 6:Atom 7:CLASS 9:CLASS 10:CLASS 13:CLASS
14:CLASS 15:CLASS 16:Atom 17:Atom 18:Atom 19:Atom 20:CLASS 21:Atom

```
L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY -  AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.


=> s L1
SAMPLE SEARCH INITIATED 12:34:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -  30824 TO ITERATE

  6.5% PROCESSED     2000 ITERATIONS                                 0 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       605985 TO   626975
PROJECTED ANSWERS:               0 TO        0

L2            0 SEA SSS SAM L1

=> s L1 full
FULL SEARCH INITIATED 12:34:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 618646 TO ITERATE

100.0% PROCESSED   618646 ITERATIONS                               32 ANSWERS
SEARCH TIME: 00.00.13

L3           32 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                               161.33     161.54

FILE 'CAPLUS' ENTERED AT 12:35:05 ON 18 AUG 2005
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 18 Aug 2005  VOL 143 ISS 8
FILE LAST UPDATED: 17 Aug 2005  (20050817/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.
```

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s L3
L4            2 L3

=> d ibib abs hitstr 1-2
```

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:370892 CAPLUS
DOCUMENT NUMBER: 140:374984
TITLE: Preparation of [[(diarylallyl)sulfanyl]phenoxy]acetic acids and esters as PPAR activators for treatment of diabetes and related conditions
INVENTOR(S): Jeppesen, Lone; Mogensen, John Patrick; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037776	A2	20040506	WO 2003-DK722	20031027
WO 2004037776	A3	20040610		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005070583	A1	20050331	US 2003-693161	20031024
CA 2503280	AA	20040506	CA 2003-2503280	20031027
EP 1558572	A2	20050803	EP 2003-757741	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

DK 2002-1631	A	20021028
DK 2003-793	A	20030526
US 2002-423467P	P	20021104
WO 2003-DK722	W	20031027

OTHER SOURCE(S): MARPAT 140:374984
GI



I



II

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

AB Title compds. I [wherein X1 and X2 = independently (un)substituted (hetero)aryl; Ar = (un)substituted arylene; Y1 and Y2 = independently O or S; Z = (CH2)n; n = 1-3; R1 = H, halo, or optionally halo-substituted (cyclo)alkyl, alkenyl, alkynyl, (hetero)aralkyl, (cyclo)alkoxy, aryloxy, (hetero)aralkoxy, (cyclo)alkylthio, or arylthio; R2 = H, (cyclo)alkyl, alkenyl, alkynyl, alkenynyl, or aryl; or pharmaceutically acceptable salts, solvates, tautomeric forms, stereoisomers, mixts. of stereoisomers, or polymorphs thereof] were prepared as peroxisome proliferator activated receptors (PPAR) activators (no data). Thus, I and their pharmaceutical compns. are useful for the treatment and/or prevention of conditions mediated by PPAR, particularly subtype PPARδ, such as diabetes, impaired glucose tolerance, insulin resistance, obesity, dyslipidemia, syndrome X, cardiovascular disease, and hypercholesteremia (no data). For example, coupling of 4,4'-dibromobenzophenone with tri-Et phosphonoacetate in toluene and THF using NaH provided Et 3,3-bis(4-bromophenyl)acrylate (73%). Reduction of the ester to the alc. (76%) using DIBAL-H in THF and toluene, followed by reaction with (4-mercapto-2-methylphenoxy)acetic acid Me ester in the presence of ADDP and tributylphosphine in THF gave II (88%).

IT **685139-17-7P**, (Z)-[4-[[3-(Benzo[b]thiophen-2-yl)-3-(4-bromophenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid
685139-24-6P, [4-[[3-(Furan-2-yl)-3-(4-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid
685139-35-9P, [4-[[3-(Benzo[b]thiophen-3-yl)-3-(4-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid
685139-38-2P, [4-[[3-(Benzo[b]thiophen-2-yl)-3-(4-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetic acid
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(PPAR activator; preparation of [[(diarylallyl)sulfanyl]phenoxy]acetates as
PPAR activators for treatment of diabetes and related conditions)

RN 685139-17-7 CAPLUS
CN Acetic acid, [4-[[(2Z)-3-benzo[b]thien-2-yl-3-(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

Double bond geometry as shown.



RN 685139-24-6 CAPLUS
CN Acetic acid, [4-[[3-(2-furanyl)-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 685139-35-9 CAPLUS
CN Acetic acid, [4-[[3-benzo[b]thien-3-yl-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 685139-38-2 CAPLUS
CN Acetic acid, [4-[[3-benzo[b]thien-2-yl-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT **685139-20-2P 685139-31-5P 685139-37-1P**
685139-40-6P 685139-48-4P, [4-[[3,3-Bis(3-methylthiophen-2-yl)allyl]sulfanyl]-2-trifluoromethylphenoxy]acetic acid
685139-51-9P, [4-[[3,3-Di(furan-2-yl)allyl]sulfanyl]-2-trifluoromethylphenoxy]acetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(PPAR activator; preparation of [[(diarylallyl)sulfanyl]phenoxy]acetates as
PPAR activators for treatment of diabetes and related conditions)

RN 685139-20-2 CAPLUS
CN L-Lysine, mono[[4-[[(2Z)-3-benzo[b]thien-2-yl-3-(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 685139-17-7
CMF C26 H21 Br O3 S2

Double bond geometry as shown.



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 685139-31-5 CAPLUS
CN L-Lysine, mono[[4-[[3-(2-furanyl)-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 685139-24-6
CMF C23 H19 F3 O4 S



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 685139-37-1 CAPLUS
CN L-Lysine, mono[[4-[[3-benzo[b]thien-3-yl-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 685139-35-9
CMF C27 H21 F3 O3 S2



RN 685139-48-4 CAPLUS
CN Acetic acid, [4-[[3,3-bis(3-methyl-2-thienyl)-2-propenyl]thio]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



RN 685139-51-9 CAPLUS
CN Acetic acid, [4-[[3,3-di-2-furanyl-2-propenyl)thio]-2-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



IT **685139-19-9P**, Ethyl (Z)-[4-[[3-(Benzo[b]thiophen-2-yl)-3-(4-bromophenyl)allyl]sulfanyl]-2-methylphenoxy]acetate **685139-30-4P**, Ethyl (Z)-[4-[[3-(Furan-2-yl)-3-(4-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetate **685139-36-0P**, Ethyl (Z)-[4-[[3-(benzo[b]thiophen-3-yl)-3-(4-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetate **685139-39-3P**, Ethyl (Z)-[4-[[3-(Benzo[b]thiophen-2-yl)-3-(4-trifluoromethylphenyl)allyl]sulfanyl]-2-methylphenoxy]acetate **685139-50-8P**, [4-[[3,3-Bis(3-methylthiophen-2-yl)allyl]sulfanyl]-2-trifluoromethylphenoxy]acetic acid



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 685139-40-6 CAPLUS
CN L-Lysine, mono[[4-[[3-benzo[b]thien-2-yl-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 685139-38-2
CMF C27 H21 F3 O3 S2



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.

ethyl ester **685139-52-0P**, [4-[[3,3-Bis(2-furanyl)allyl]sulfanyl]-2-trifluoromethylphenoxy]acetic acid ethyl ester
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; prepn. of [[(diarylallyl)sulfanyl]phenoxy]acetates as PPAR activators for treatment of diabetes and related conditions)

RN 685139-19-9 CAPLUS
CN Acetic acid, [4-[[(2Z)-3-benzo[b]thien-2-yl-3-(4-bromophenyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 685139-30-4 CAPLUS
CN Acetic acid, [4-[[(2Z)-3-(2-furanyl)-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 685139-36-0 CAPLUS
CN Acetic acid, [4-[[(2Z)-3-benzo[b]thien-3-yl-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 685139-39-3 CAPLUS
CN Acetic acid, [4-[[(2Z)-3-benzo[b]thien-2-yl-3-[4-(trifluoromethyl)phenyl]-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 685139-50-8 CAPLUS
CN Acetic acid, [4-[(3,3-bis(3-methyl-2-thienyl)-2-propenyl]thio]-2-(trifluoromethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 685139-52-0 CAPLUS
CN Acetic acid, [4-[(3,3-di-2-furanyl-2-propenyl)thio]-2-

(trifluoromethyl)phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2004:370891 CAPLUS
DOCUMENT NUMBER: 140:391127
TITLE: Preparation of biphenylallylsulfanylphenoxyacetates and related compounds for treating peroxisome proliferator activated receptor (PPAR) mediated diseases
INVENTOR(S): Jeppesen, Lone; Pettersson, Ingrid; Sauerberg, Per; Pihera, Pavel; Havranek, Miroslav
PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.
SOURCE: PCT Int. Appl., 69 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004037775	A1	20040506	WO 2003-DK723	20031027
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005080115	A1	20050414	US 2003-692561	20031024
CA 2503276	AA	20040506	CA 2003-2503276	20031027
EP 1558571	A1	20050803	EP 2003-757742	20031027
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

DK 2002-1629	A	20021028
US 2002-423644P	P	20021104
WO 2003-DK723	W	20031027

OTHER SOURCE(S): MARPAT 140:391127
GI



I

AB Title compds. [I; X1, X3 = (substituted) aryl, heteroaryl; X2, Ar = (substituted) aryl, arylene; Y1, YZ = O, S; Z = (CH2)n; n = 1-3; R1 = H, halo, (substituted) alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, heteroaralkyl, alkoxy, cycloalkoxy, alkylthio, etc.; R2 = H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, etc.], were prepared for treatment of PPAR mediated disease (no data). Thus, [4-[3,3-bis-(4-bromophenyl)allylsulfanyl]-2-methylphenoxy]acetic acid (preparation given), PhB(OH)2, KF, Pd2(dba)3, and Pd[P(tBu)3]2 were stirred in THF to give [4-[3-biphenyl-4-yl-3-(4-bromophenyl)allylsulfanyl]phenoxy]acetic acid.

IT 686774-28-7P 686774-29-8P 686774-30-1P
686774-31-2P 686774-32-3P 686775-59-7P
686775-62-2P 686775-64-4P 686775-66-6P

686775-68-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of biphenylallylsulfanylphenoxyacetates and related compds. for treating peroxisome proliferator activated receptor (PPAR) mediated diseases)

RN 686774-28-7 CAPLUS
CN Acetic acid, [2-methyl-4-[[3-[5-(5-methyl-2-thienyl)-2-benzofuranyl]-3-(2-thienyl)-2-propenyl]thio]phenoxy]- (9CI) (CA INDEX NAME)



RN 686774-29-8 CAPLUS
CN Acetic acid, [4-[[3-[1,1'-biphenyl]-4-yl-3-(2-furanyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 686774-30-1 CAPLUS
CN Acetic acid, [4-[(3-benzo[b]thien-3-yl-3-[1,1'-biphenyl]-4-yl-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 686774-31-2 CAPLUS
CN Acetic acid, [4-[(3-benzo[b]thien-2-yl-3-[1,1'-biphenyl]-4-yl-2-propenyl)thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 686774-32-3 CAPLUS
CN Acetic acid, [4-[[3-[1,1'-biphenyl]-4-yl-3-(5-methyl-2-thienyl)-2-propenyl]thio]-2-methylphenoxy]- (9CI) (CA INDEX NAME)



RN 686775-59-7 CAPLUS
CN L-Lysine, mono[(2-methyl-4-[[3-[5-(5-methyl-2-thienyl)-2-benzofuranyl]-3-(2-thienyl)-2-propenyl]thio]phenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 686774-28-7
CMF C29 H24 O4 S3



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 686775-62-2 CAPLUS
CN L-Lysine, mono[[4-[[3-[1,1'-biphenyl]-4-yl-3-(2-furanyl)-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 686774-29-8
CMF C28 H24 O4 S



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 686775-64-4 CAPLUS
CN L-Lysine, mono[[4-[(3-benzo[b]thien-3-yl-3-[1,1'-biphenyl]-4-yl-2-propenyl)thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 686774-30-1
CMF C32 H26 O3 S2



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 686775-66-6 CAPLUS
CN L-Lysine, mono[[4-[(3-benzo[b]thien-2-yl-3-[1,1'-biphenyl]-4-yl-2-propenyl)thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 686774-31-2
CMF C32 H26 O3 S2



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 686775-68-8 CAPLUS
CN L-Lysine, mono[[4-[[3-[1,1'-biphenyl]-4-yl-3-(5-methyl-2-thienyl)-2-propenyl]thio]-2-methylphenoxy]acetate] (9CI) (CA INDEX NAME)

CM 1

CRN 686774-32-3
CMF C29 H26 O3 S2



CM 2

CRN 56-87-1
CMF C6 H14 N2 O2

Absolute stereochemistry.



IT 686775-57-5P 686775-58-6P 686775-61-1P
686775-63-3P 686775-65-5P 686775-67-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of biphenylallylsulfanylphenoxyacetates and related compds. for
treating peroxisome proliferator activated receptor (PPAR) mediated diseases)

RN 686775-57-5 CAPLUS
CN Acetic acid, [4-[[3-(5-bromo-2-benzofuranyl)-3-(2-thienyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 686775-58-6 CAPLUS
CN Acetic acid, [2-methyl-4-[[3-[5-(5-methyl-2-thienyl)-2-benzofuranyl]-3-(2-thienyl)-2-propenyl]thio]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 686775-61-1 CAPLUS
CN Acetic acid, [4-[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(2-furanyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 686775-63-3 CAPLUS
CN Acetic acid, [4-[(3-benzo[b]thien-3-yl-3-[1,1'-biphenyl]-4-yl-2-propenyl)thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 686775-65-5 CAPLUS

CN Acetic acid, [4-[(3-benzo[b]thien-2-yl-3-[1,1'-biphenyl]-4-yl-2-propenyl)thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 686775-67-7 CAPLUS
CN Acetic acid, [4-[[(2Z)-3-[1,1'-biphenyl]-4-yl-3-(5-methyl-2-thienyl)-2-propenyl]thio]-2-methylphenoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.33	171.87

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.46	-1.46

STN INTERNATIONAL LOGOFF AT 12:35:33 ON 18 AUG 2005